Alterations in the ErbB family (namely ErbB1 (EGFR/HER1), the orphan receptor ErbB2 (HER2 or Neu), ErbB3 (HER3), and ErbB4 (HER4)) have been associated with BC incidence and poor prognosis [18,19] and mutations of ErbB effectors are among the most common genetic abnormalities associated with breast cancer [20]. This evidence concerns the gene ERBB2 and breast cancer.